• Mizuho Securities sets a price target of $22 for NASDAQ:SGRY, indicating a potential upside of 44.74%.
• Significant surge in options trading activity with a 498% increase in put options.
• Analyst ratings vary significantly, from Cantor Fitzgerald's "overweight" rating with a $36 price target to Weiss Ratings' "sell (d-)" rating.

Surgery Partners, Inc. (NASDAQ:SGRY) is a healthcare services company that operates surgical facilities across the United States. It provides a range of services, including outpatient surgery, diagnostic imaging, and laboratory services. The company competes with other healthcare service providers, focusing on delivering cost-effective surgical solutions.

On November 17, 2025, Mizuho Securities set a price target of $22 for SGRY, suggesting a potential upside of 44.74% from its current trading price of $15.20. This optimistic outlook contrasts with the recent trading activity, where the stock price has decreased to $15.06, a drop of 1.47% or $0.22. The stock has fluctuated between $15.01 and $15.57 today.

SGRY has seen a significant surge in options trading activity, with traders acquiring 6,122 put options, a 498% increase from the average volume of 1,024 put options. This heightened activity may indicate investor uncertainty or hedging strategies. Despite this, Cantor Fitzgerald maintains an "overweight" rating with a $36 price target, while the Royal Bank of Canada has set a $31 target with an "outperform" rating.

Benchmark recently adjusted its price target for SGRY from $35 to $30, maintaining a "buy" rating. In contrast, Weiss Ratings reaffirmed a "sell (d-)" rating, highlighting differing analyst opinions. The stock's market capitalization stands at approximately $1.95 billion, with a trading volume of 1,356,144 shares on the NASDAQ exchange.

SGRY's stock has experienced a 52-week high of $26.16 and a low of $15.01, reflecting its volatile nature. Despite the mixed analyst ratings and recent price fluctuations, Mizuho Securities' price target suggests potential growth, offering investors a reason to watch the stock closely.